Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue
- PMID: 16094706
- PMCID: PMC4615407
- DOI: 10.3748/wjg.v11.i30.4661
Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue
Abstract
Aim: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
Methods: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
Results: Immunohistochemical analysis of MUC1 expression showed that in the 96 PLC samples, 68 (70.8%) were strong positive, and 6 (6.2%) were weak positive. Only 4 in the 20 cirrhotic liver tissues were found to be weak positive, while no expression of MUC1 was detected in normal liver tissues. Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues. The expressed MUC1 protein, stained in dark brownish or brownish-yellow particles, chiefly localized on the cancer cell membranes or in cytoplasm. In the 68 strong positive samples, 40 were detected on cell membrane and the other 28 were in cytoplasm. In addition, follow-up studies of those PLC cases demonstrated that MUC1 expression on cell membrane or in cytoplasm was closely associated with PLC prognosis. The expression of MUC1 in PLC had little statistical significance in respect of the pathological types and sizes of the tumors, but a strong relationship regarding histological differentiation, metastasis of lymph nodes, portal canal emboli, and post-operational recurrence of the carcinomas. After 3 years of tumor excision, the metastasis rate in MUC1 positive expression group (67.6%) was much higher than that in MUC1 weak expression group (33.3%) and negative expression group (31.8%), and thus the survival rate in MUC1-positive expression group was significantly different from that in weak and negative expression groups.
Conclusion: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
Figures


Similar articles
-
Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis.Int J Mol Sci. 2019 Mar 14;20(6):1288. doi: 10.3390/ijms20061288. Int J Mol Sci. 2019. PMID: 30875782 Free PMC article. Review.
-
Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma.J Hepatobiliary Pancreat Surg. 2006;13(3):245-51. doi: 10.1007/s00534-005-1070-4. J Hepatobiliary Pancreat Surg. 2006. PMID: 16708303
-
An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.Pathol Int. 1999 Apr;49(4):310-7. doi: 10.1046/j.1440-1827.1999.00865.x. Pathol Int. 1999. PMID: 10365850
-
Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.Pathol Oncol Res. 2019 Oct;25(4):1363-1371. doi: 10.1007/s12253-018-0386-8. Epub 2018 Feb 20. Pathol Oncol Res. 2019. PMID: 29464551
-
Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers.Biosci Trends. 2009 Dec;3(6):220-32. Biosci Trends. 2009. PMID: 20103851 Review.
Cited by
-
Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.Oncotarget. 2015 Feb 28;6(6):4253-65. doi: 10.18632/oncotarget.2973. Oncotarget. 2015. PMID: 25714018 Free PMC article.
-
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.Sci Rep. 2021 Mar 18;11(1):6276. doi: 10.1038/s41598-021-85747-9. Sci Rep. 2021. PMID: 33737613 Free PMC article.
-
Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder.Urol Ann. 2011 Jan;3(1):8-13. doi: 10.4103/0974-7796.75857. Urol Ann. 2011. PMID: 21346826 Free PMC article.
-
Novel Cellular Therapies for Hepatocellular Carcinoma.Cancers (Basel). 2022 Jan 20;14(3):504. doi: 10.3390/cancers14030504. Cancers (Basel). 2022. PMID: 35158772 Free PMC article. Review.
-
Dynamic clustering of genomics cohorts beyond race, ethnicity-and ancestry.BMC Med Genomics. 2025 May 15;18(1):87. doi: 10.1186/s12920-025-02154-z. BMC Med Genomics. 2025. PMID: 40375077 Free PMC article.
References
-
- Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139:766–774. - PubMed
-
- Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003;81:195–207. - PubMed
-
- Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer. 2001;91:1973–1982. - PubMed
-
- von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers. 2000;15:343–356. - PubMed
-
- Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol. 2004;121:884–892. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous